Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Diabetic Painful Neuropathy, Followed by a Double-Blind Safety Extension and an Open-Label Safety Extension
Conditions
Interventions
JNJ-42160443 (1 mg)
JNJ-42160443 (3 mg)
+2 more
Locations
23
United States
Jonesboro, Arkansas, United States
Fresno, California, United States
La Jolla, California, United States
Long Beach, California, United States
Redondo Beach, California, United States
Tustin, California, United States
Start Date
November 1, 2009
Primary Completion Date
June 1, 2011
Completion Date
June 1, 2011
Last Updated
June 3, 2016
NCT06857994
NCT07141992
NCT07317284
NCT06524284
NCT07236723
NCT05165368
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions